22 min listen
Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposiu…
Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposiu…
ratings:
Length:
62 minutes
Released:
Mar 21, 2024
Format:
Podcast episode
Description
Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.
CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary2).
CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary2).
Released:
Mar 21, 2024
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love